메뉴 건너뛰기
Antimicrobial Agents and Chemotherapy
Volumn 60, Issue 7, 2016, Pages 4264-4273
A pathogen-selective antibiotic minimizes disturbance to the microbiome
Author keywords

[No Author keywords available]
Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BACTERIAL DNA; BACTERIAL RNA; CLINDAMYCIN; LINEZOLID; MOXIFLOXACIN; N METHYL N [(3 METHLBENZOFURAN 2 YL)METHYL] 3 ( 7 OXO 5,6,7,8 TETRAHYDRO 1,8 NAPTHYRIDIN 3 YL)ACRYLAMIDE; RNA 16S; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;
EID: 84975521673     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00535-16     Document Type: Article
Times cited : (50)
References (38)
  • 1
    • 0001354030 scopus 로고
    • Enhanced susceptibility to Salmonella infection in streptomycin-treated mice
    • Bohnhoff M, Miller CP. 1962. Enhanced susceptibility to Salmonella infection in streptomycin-treated mice. J Infect Dis 111:117-127. http://dx.doi.org/10.1093/infdis/111.2.117.
    • (1962) J Infect Dis , vol.111 , pp. 117-127
    • Bohnhoff, M.1    Miller, C.P.2
  • 2
    • 84857067037 scopus 로고    scopus 로고
    • Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis
    • Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda C, Xavier J, Pamer EG. 2012. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun 80:62-73. http://dx.doi.org/10.1128/IAI.05496-11.
    • (2012) Infect Immun , vol.80 , pp. 62-73
    • Buffie, C.G.1    Jarchum, I.2    Equinda, M.3    Lipuma, L.4    Gobourne, A.5    Viale, A.6    Ubeda, C.7    Xavier, J.8    Pamer, E.G.9
  • 3
    • 70449703996 scopus 로고    scopus 로고
    • What are the consequences of the disappearing human microbiota?
    • Blaser MJ, Falkow S. 2009. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol 7:887-894. http://dx.doi.org/10.1038/nrmicro2245.
    • (2009) Nat Rev Microbiol , vol.7 , pp. 887-894
    • Blaser, M.J.1    Falkow, S.2
  • 4
    • 84930607200 scopus 로고    scopus 로고
    • The effect of past antibiotic exposure on diabetes risk
    • Boursi B, Mamtani R, Haynes K, Yang YX. 2015. The effect of past antibiotic exposure on diabetes risk. Eur J Endocrinol 172:639-648. http://dx.doi.org/10.1530/EJE-14-1163.
    • (2015) Eur J Endocrinol , vol.172 , pp. 639-648
    • Boursi, B.1    Mamtani, R.2    Haynes, K.3    Yang, Y.X.4
  • 6
    • 84879827689 scopus 로고    scopus 로고
    • Antibiotic exposure and the development of coeliac disease: A nationwide case-control study
    • Mårild K, Ye W, Lebwohl B, Green PH, Blaser MJ, Card T, Ludvigsson JF. 2013. Antibiotic exposure and the development of coeliac disease: a nationwide case-control study. BMC Gastroenterol 13:109. http://dx.doi.org/10.1186/1471-230X-13-109.
    • (2013) BMC Gastroenterol , vol.13 , pp. 109
    • Mårild, K.1    Ye, W.2    Lebwohl, B.3    Green, P.H.4    Blaser, M.J.5    Card, T.6    Ludvigsson, J.F.7
  • 7
    • 84907486974 scopus 로고    scopus 로고
    • Antibiotics and the gut microbiota
    • Modi SR, Collins JJ, Relman DA. 2014. Antibiotics and the gut microbiota. J Clin Invest 124:4212-4218. http://dx.doi.org/10.1172/JCI72333.
    • (2014) J Clin Invest , vol.124 , pp. 4212-4218
    • Modi, S.R.1    Collins, J.J.2    Relman, D.A.3
  • 8
    • 78049494788 scopus 로고    scopus 로고
    • Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome
    • Jakobsson HE, Jernberg C, Andersson AF, Sjölund-Karlsson M, Jansson JK, Engstrand L. 2010. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One 5:e9836. http://dx.doi.org/10.1371/journal.pone.0009836.
    • (2010) PLoS One , vol.5
    • Jakobsson, H.E.1    Jernberg, C.2    Andersson, A.F.3    Sjölund-Karlsson, M.4    Jansson, J.K.5    Engstrand, L.6
  • 9
    • 79952756960 scopus 로고    scopus 로고
    • Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation
    • Dethlefsen L, Relman DA. 2011. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 108:4554-4561. http://dx.doi.org/10.1073/pnas.1000087107.
    • (2011) Proc Natl Acad Sci U S A , vol.108 , pp. 4554-4561
    • Dethlefsen, L.1    Relman, D.A.2
  • 10
    • 78049522796 scopus 로고    scopus 로고
    • Long-term impacts of antibiotic exposure on the human intestinal microbiota
    • Jernberg C, Lofmark S, Edlund C, Jansson JK. 2010. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 156:3216-3223. http://dx.doi.org/10.1099/mic.0.040618-0.
    • (2010) Microbiology , vol.156 , pp. 3216-3223
    • Jernberg, C.1    Lofmark, S.2    Edlund, C.3    Jansson, J.K.4
  • 11
    • 84924939876 scopus 로고    scopus 로고
    • How bacterial pathogens eat host lipids: Implications for the development of fatty acid synthesis therapeutics
    • Yao J, Rock CO. 2015. How bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics. J Biol Chem 290:5940-5946. http://dx.doi.org/10.1074/jbc.R114.636241.
    • (2015) J Biol Chem , vol.290 , pp. 5940-5946
    • Yao, J.1    Rock, C.O.2
  • 12
    • 84890919902 scopus 로고    scopus 로고
    • Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI)
    • Yao J, Maxwell JB, Rock CO. 2013. Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI). J Biol Chem 288:36261-36271. http://dx.doi.org/10.1074/jbc.M113.512905.
    • (2013) J Biol Chem , vol.288 , pp. 36261-36271
    • Yao, J.1    Maxwell, J.B.2    Rock, C.O.3
  • 13
    • 84893492498 scopus 로고    scopus 로고
    • The Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy
    • Cummings JE, Kingry LC, Rholl DA, Schweizer HP, Tonge PJ, Slayden RA. 2014. The Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy. Antimicrob Agents Chemother 58:931-935. http://dx.doi.org/10.1128/AAC.00176-13.
    • (2014) Antimicrob Agents Chemother , vol.58 , pp. 931-935
    • Cummings, J.E.1    Kingry, L.C.2    Rholl, D.A.3    Schweizer, H.P.4    Tonge, P.J.5    Slayden, R.A.6
  • 15
    • 34447263022 scopus 로고    scopus 로고
    • In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea
    • Yum JH, Kim CK, Yong D, Lee K, Chong Y, Kim CM, Kim JM, Ro S, Cho JM. 2007. In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob Agents Chemother 51:2591-2593. http://dx.doi.org/10.1128/AAC.01562-06.
    • (2007) Antimicrob Agents Chemother , vol.51 , pp. 2591-2593
    • Yum, J.H.1    Kim, C.K.2    Yong, D.3    Lee, K.4    Chong, Y.5    Kim, C.M.6    Kim, J.M.7    Ro, S.8    Cho, J.M.9
  • 16
    • 34848874500 scopus 로고    scopus 로고
    • CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor
    • Park HS, Yoon YM, Jung SJ, Yun IN, Kim CM, Kim JM, Kwak JH. 2007. CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. Int J Antimicrob Agents 30:446-451. http://dx.doi.org/10.1016/j.ijantimicag.2007.07.006.
    • (2007) Int J Antimicrob Agents , vol.30 , pp. 446-451
    • Park, H.S.1    Yoon, Y.M.2    Jung, S.J.3    Yun, I.N.4    Kim, C.M.5    Kim, J.M.6    Kwak, J.H.7
  • 18
    • 84883642207 scopus 로고    scopus 로고
    • AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects
    • Kaplan N, Garner C, Hafkin B. 2013. AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects. Eur J Pharm Sci 50:440-446. http://dx.doi.org/10.1016/j.ejps.2013.08.019.
    • (2013) Eur J Pharm Sci , vol.50 , pp. 440-446
    • Kaplan, N.1    Garner, C.2    Hafkin, B.3
  • 19
    • 84948157799 scopus 로고    scopus 로고
    • Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release tablets in healthy subjects
    • Hafkin B, Kaplan N, Hunt T. 2015. Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release tablets in healthy subjects. Future Microbiol 10:1805-1813. http://dx.doi.org/10.2217/fmb.15.101.
    • (2015) Future Microbiol , vol.10 , pp. 1805-1813
    • Hafkin, B.1    Kaplan, N.2    Hunt, T.3
  • 20
    • 84873134560 scopus 로고    scopus 로고
    • Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model
    • Banevicius MA, Kaplan N, Hafkin B, Nicolau DP. 2013. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model. J Chemother 25:26-31. http://dx.doi.org/10.1179/1973947812Y.0000000061.
    • (2013) J Chemother , vol.25 , pp. 26-31
    • Banevicius, M.A.1    Kaplan, N.2    Hafkin, B.3    Nicolau, D.P.4
  • 21
    • 0034644010 scopus 로고    scopus 로고
    • A triclosan-resistant bacterial enzyme
    • Heath RJ, Rock CO. 2000. A triclosan-resistant bacterial enzyme. Nature 406:145-146. http://dx.doi.org/10.1038/35018162.
    • (2000) Nature , vol.406 , pp. 145-146
    • Heath, R.J.1    Rock, C.O.2
  • 23
    • 67849088246 scopus 로고    scopus 로고
    • AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity
    • Karlowsky JA, Kaplan N, Hafkin B, Hoban DJ, Zhanel GG. 2009. AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrob Agents Chemother 53:3544-3548. http://dx.doi.org/10.1128/AAC.00400-09.
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 3544-3548
    • Karlowsky, J.A.1    Kaplan, N.2    Hafkin, B.3    Hoban, D.J.4    Zhanel, G.G.5
  • 24
    • 84931292121 scopus 로고    scopus 로고
    • Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains
    • Flamm RK, Rhomberg PR, Kaplan N, Jones RN, Farrell DJ. 2015. Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. Antimicrob Agents Chemother 59:2583-2587. http://dx.doi.org/10.1128/AAC.05119-14.
    • (2015) Antimicrob Agents Chemother , vol.59 , pp. 2583-2587
    • Flamm, R.K.1    Rhomberg, P.R.2    Kaplan, N.3    Jones, R.N.4    Farrell, D.J.5
  • 25
    • 84907528345 scopus 로고    scopus 로고
    • Effects of antibiotics on human microbiota and subsequent disease
    • Keeney KM, Yurist-Doutsch S, Arrieta MC, Finlay BB. 2014. Effects of antibiotics on human microbiota and subsequent disease. Annu Rev Microbiol 68:217-235. http://dx.doi.org/10.1146/annurev-micro-091313-103456.
    • (2014) Annu Rev Microbiol , vol.68 , pp. 217-235
    • Keeney, K.M.1    Yurist-Doutsch, S.2    Arrieta, M.C.3    Finlay, B.B.4
  • 26
    • 67650076454 scopus 로고    scopus 로고
    • Prolonged impact of antibiotics on intestinal microbial ecology and susceptibility to enteric Salmonella infection
    • Croswell A, Amir E, Teggatz P, Barman M, Salzman NH. 2009. Prolonged impact of antibiotics on intestinal microbial ecology and susceptibility to enteric Salmonella infection. Infect Immun 77:2741-2753. http://dx.doi.org/10.1128/IAI.00006-09.
    • (2009) Infect Immun , vol.77 , pp. 2741-2753
    • Croswell, A.1    Amir, E.2    Teggatz, P.3    Barman, M.4    Salzman, N.H.5
  • 27
    • 0013909023 scopus 로고
    • Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man
    • Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. 1966. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50:219-244.
    • (1966) Cancer Chemother Rep , vol.50 , pp. 219-244
    • Freireich, E.J.1    Gehan, E.A.2    Rall, D.P.3    Schmidt, L.H.4    Skipper, H.E.5
  • 29
    • 0036146824 scopus 로고    scopus 로고
    • Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set
    • Nadkarni M, Martin F, Jacques N, Hunter N. 2002. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology 148:257-266. http://dx.doi.org/10.1099/00221287-148-1-257.
    • (2002) Microbiology , vol.148 , pp. 257-266
    • Nadkarni, M.1    Martin, F.2    Jacques, N.3    Hunter, N.4
  • 32
    • 24044447664 scopus 로고    scopus 로고
    • Automated generation of heuristics for biological sequence comparison
    • Slater GS, Birney E. 2005. Automated generation of heuristics for biological sequence comparison. BMC Bioinformatics 6:31. http://dx.doi.org/10.1186/1471-2105-6-31.
    • (2005) BMC Bioinformatics , vol.6 , pp. 31
    • Slater, G.S.1    Birney, E.2
  • 33
    • 77957244650 scopus 로고    scopus 로고
    • Search and clustering orders of magnitude faster than BLAST
    • Edgar RC. 2010. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26:2460-2461. http://dx.doi.org/10.1093/bioinformatics/btq461.
    • (2010) Bioinformatics , vol.26 , pp. 2460-2461
    • Edgar, R.C.1
  • 34
    • 84876427223 scopus 로고    scopus 로고
    • Phyloseq: An R package for reproducible interactive analysis and graphics of microbiome census data
    • McMurdie PJ, Holmes S. 2013. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 8:e61217. http://dx.doi.org/10.1371/journal.pone.0061217.
    • (2013) PLoS One , vol.8
    • McMurdie, P.J.1    Holmes, S.2
  • 35
    • 80053084113 scopus 로고    scopus 로고
    • Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors
    • Parsons JB, Frank MW, Subramanian C, Saenkham P, Rock CO. 2011. Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. Proc Natl Acad Sci U S A 108:15378-15383. http://dx.doi.org/10.1073/pnas.1109208108.
    • (2011) Proc Natl Acad Sci U S A , vol.108 , pp. 15378-15383
    • Parsons, J.B.1    Frank, M.W.2    Subramanian, C.3    Saenkham, P.4    Rock, C.O.5
  • 36
    • 84952883244 scopus 로고    scopus 로고
    • Activation of exogenous fatty acids to acyl-acyl carrier protein cannot bypass FabI inhibition in Neisseria
    • Yao J, Bruhn DF, Frank MW, Lee RE, Rock CO. 2016. Activation of exogenous fatty acids to acyl-acyl carrier protein cannot bypass FabI inhibition in Neisseria. J Biol Chem 291:171-181. http://dx.doi.org/10.1074/jbc.M115.699462.
    • (2016) J Biol Chem , vol.291 , pp. 171-181
    • Yao, J.1    Bruhn, D.F.2    Frank, M.W.3    Lee, R.E.4    Rock, C.O.5
  • 37
    • 84864512716 scopus 로고    scopus 로고
    • Expression, purification and characterization of enoyl-ACP reductase II, FabK, from Porphyromonas gingivalis
    • Hevener KE, Mehboob S, Boci T, Truong K, Santarsiero BD, Johnson ME. 2012. Expression, purification and characterization of enoyl-ACP reductase II, FabK, from Porphyromonas gingivalis. Protein Expr Purif 85:100-108. http://dx.doi.org/10.1016/j.pep.2012.07.003.
    • (2012) Protein Expr Purif , vol.85 , pp. 100-108
    • Hevener, K.E.1    Mehboob, S.2    Boci, T.3    Truong, K.4    Santarsiero, B.D.5    Johnson, M.E.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.